Non-Hodgkin’s Lymphoma (NHL) Information Center
Each year in the United States, more than 66,000 people are diagnosed with non-Hodgkin’s lymphoma. Thanks to improvements in treatment, non-Hodgkin’s lymphoma patients are living longer. It is estimated that there are more than 400,000 non-Hodgkin’s lymphoma survivors living in the U.S. today.
Advances in chemotherapy, targeted therapy, and radiation therapy have all contributed to improved non-Hodgkin’s lymphoma survival. In addition, advances in supportive care have made non-Hodgkin’s lymphoma treatment more tolerable, leading to improved quality of life.
Understanding non-Hodgkin’s lymphoma treatment options, the role of different doctors specializing in the treatment of non-Hodgkin’s lymphoma, and how and when to access new and innovative non-Hodgkin’s lymphoma treatment options available through clinical trials is essential in order to achieve the best outcome from non-Hodgkin’s lymphoma treatment.
The Cancer Consultants Non-Hodgkin’s Lymphoma Information Center has been designed to help patients understand non-Hodgkin’s lymphoma and non-Hodgkin’s lymphoma treatment options while providing ongoing information, inspiration, support, and community to individuals affected by a diagnosis of non-Hodgkin’s lymphoma.
Headline NHL News 
Approximately 16% of Worldwide Cancers Caused By Preventable Infections
About 16% of cancers worldwide are the result of preventable and treatable infections.
Aspirin Continues to Look Promising for Cancer Prevention
Study reports fewer cases and fewer deaths with daily use.
Lymphoma During Pregnancy Can Have Good Outcomes
In many cases, both mother and baby do well.
Non-Hodgkin's Lymphoma Tips
Men, Fertility, and Cancer Men who confront a cancer diagnosis before beginning or completing their families...
Women, Fertility and Cancer Women who confront a cancer diagnosis before beginning or completing their families...
What is Genomics? You’ve probably heard of genetic testing for cancer susceptibility, but the more...
Non-Hodgkin’s Lymphoma Management
Inspiration, Hope & Resources
On Top of the World: Climbing Everest & Beating Cancer Twice Sean Swarner is a master of setting a goal and achieving it. So when he...
Jack & Jill Late Stage Cancer Foundation Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the...
Moving Bodies, Changing Lives Moving On Aerobics helps women regain joy of movement and physical fitness after...
Non-Hodgkin's Lymphoma Conference Coverage
ASCO 2009: Advances in Treatment of Aggressive B- and T-Cell Non-Hodgkin’s Lymphoma Date: May 29 – June 2, 2009 Location: Orlando, Florida Author: C. Dean Buckner,...
Non-Hodgkin’s Lymphoma Clinical Trials
COGANHL01P1 – A Pilot study to determine the Toxicity of the addition of Rituximab to the Inducation and Consolidation phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-cell leukemia/lymphoma treated with LMB/FAB Therapy
SeaGenMarinerStudy – A Randomized Phase IIb Placebo-controlled study of R-ICE Chemotherapy (RItuximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for second-line treatment of patients with diffuse large B-cell lymphoma (DLBCL)
114-NH-301 – Phase III, Randomized, Double-blind Study of Glaiximab in combination with Rituximab compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non-Hodgkin’s Lymphoma.
 |
 |
 |
 |
